Shareholder rights law firm Robbins LLP announces that a purchaser of Aurora Cannabis, Inc. has filed a class action complaint against the company's officers for alleged violations of the Securities Exchange Act of 1934 between February 13, 2020 and September 4, 2020. Based in Edmonton, Canada, Aurora produces and distributes medical cannabis products worldwide. If you suffered a loss due to Aurora Cannabis, Inc.'s ...

Shareholder rights law firm Robbins LLP announces that a purchaser of Aurora Cannabis, Inc. (NYSE: ACB) has filed a class action complaint against the company's officers for alleged violations of the Securities Exchange Act of 1934 between February 13, 2020 and September 4, 2020. Based in Edmonton, Canada, Aurora produces and distributes medical cannabis products worldwide.

If you suffered a loss due to Aurora Cannabis, Inc.'s misconduct, click here .

Aurora Cannabis, Inc. (ACB) Accused of Failing to Disclose Sizable Impairment Charges

According to the complaint, during the relevant period, Aurora Cannabis, Inc. failed to disclose that it had significantly overpaid for recently acquired assets while the value of others depreciated. When Canada passed the Cannabis Act in 2018 and reshaped the marijuana industry, Aurora completed a series of acquisitions intended to strengthen its position in the marketplace, including the purchase of MedReleaf, a medical cannabis producer, for 3.2 billion Canadian dollars. Aurora encountered issues such as regulatory delays, overproduction, and black market competition. On February 6, 2020, Aurora issued a press release detailing its business transformation plan, aimed at better aligning the company with the "current realities of the cannabis market." However, the plan was inadequate in addressing the company's situation. The plan's shortfall was even further evident after Aurora's September 8, 2020 press release, which revealed that the company expected to record $1.8 billion in goodwill charges in 2020's fourth quarter, including up to $90 million in fixed asset impairment charges, and $140 million to carry the value of certain inventory. On this news, Aurora stock price fell 11.63% to close at $7.52 per share on September 8, 2020.

If you purchased Aurora Cannabis, Inc. (ACB) securities between February 13, 2020 and September 4, 2020, you have until December 1, 2020, to ask the court to appoint you lead plaintiff for the class.

Contact us to learn more:
Lauren Levi
(800) 350-6003
llevi@robbinsllp.com
Shareholder Information Form

Robbins LLP is a nationally recognized leader in shareholder rights law. To be notified if a class action against Aurora Cannabis, Inc. settles or to receive free alerts about companies engaged in wrongdoing, sign up for Stock Watch today.

Attorney Advertising. Past results do not guarantee a similar outcome.

Lauren Levi
Robbins LLP
5040 Shoreham Place
San Diego, CA 92122
llevi@robbinsllp.com
(800) 350-6003
www.robbinsllp.com

News Provided by Business Wire via QuoteMedia

Numinus Develops Proprietary Psychedelic Tests with New Toxicity and Potency Scans

Numinus Develops Proprietary Psychedelic Tests with New Toxicity and Potency Scans

Analytical testing will accelerate Numinus' Research and Development capabilities and generate revenue through third-party clients

Numinus Wellness Inc. ("Numinus" or the "Company") (TSXV: NUMI), a leader in psychedelics-focused mental healthcare, has today announced novel, proprietary methods for psychedelic mushroom compound screening. The testing, which was developed and validated in-house, will be available as part of its service offerings for third-party clients and used for evidence-based conversations with the regulators.

Keep reading... Show less

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors Cronos Group Inc. - CRON1111

Pomerantz LLP is investigating claims on behalf of investors of Cronos Group Inc. ("Cronos" or the "Company") (NASDAQ: CRON). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.

The investigation concerns whether Cronos and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

Keep reading... Show less
cannabis plant layered with German flag graphic

Cannabis Weekly Round-Up: Germany Moves Ahead on Path to Adult Use

Three political parties have formed a coalition in Germany, leading to a new government, and it has promised cannabis reform in the European nation.

Meanwhile, a popular cannabis retailer confirmed consumers will now find its products available for delivery on the Uber Eats mobile application in Ontario.

Keep reading to find out more cannabis highlights from the past five days.

Keep reading... Show less
HEMPSANA Announces Q3 2021 Financial Results

HEMPSANA Announces Q3 2021 Financial Results

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION, DISTRIBUTION OR DISSEMINATION DIRECTLY, OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES.

Hempsana Holdings Ltd. (the " Company " or " Hempsana ") today announced third quarter ("Q3") financial results for the three- and nine-month period ended September 30, 2021.

Keep reading... Show less
Numinus Receives Conditional Approval to Graduate to the Toronto Stock Exchange

Numinus Receives Conditional Approval to Graduate to the Toronto Stock Exchange

 Numinus Wellness Inc. ("Numinus" or the "Company") (TSXV: NUMI), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, is pleased to announce that it has received conditional approval from the Toronto Stock Exchange ("TSX") to graduate its listing from the TSX Venture Exchange (the "TSXV") to the TSX.

"This is an important milestone for Numinus, as we take key steps to heighten our corporate profile and reach a broader range of investors," said Payton Nyquvest , Founder and CEO of Numinus. "Today's announcement is reflective of many exciting developments occurring at Numinus. We're actively growing our clinic network across North America , expanding our lab capabilities, and strategically investing in clinical research to drive long-term value creation for our investors."

Keep reading... Show less
MediPharm Labs Completes Medical Cannabis Export to Barbados

MediPharm Labs Completes Medical Cannabis Export to Barbados

  • Patient based delivery of medical cannabis executed with approval from both Barbados and Canadian Health Authorities.
  • This marks the fourth new country entered by MediPharm Labs in 2021, following initial shipments to Germany, Brazil and Peru.

MediPharm Labs Corp . (TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) ("MediPharm Labs" or the "Company") a pharmaceutical company specialized in precision-based cannabinoids, is pleased to announce it has completed a medical cannabis export to Barbados in conjunction with strategic partner Avicanna (TSX: AVCN).

"Our GMP platform make us the go-to partner for companies looking to access global medical cannabis programs," said Bryan Howcroft, CEO, MediPharm Labs. "As countries around the world continue to adopt medical cannabis programs, MediPharm Labs is best positioned to serve these markets as the only North American producer with a Drug Establishment License (GMP) for the extraction of natural cannabinoids."

Keep reading... Show less

Top News

Related News